Stoke Therapeutics Builds Commercial Infrastructure as Clinical Catalysts Approach
Stoke Therapeutics is expanding market-access teams while two data readouts approach, but preparation is not proof of approval or commercial…
Cocrystal Pharma’s Widening Loss Meets Fresh OPKO Backing and Norovirus Trial Progress
Nasdaq-listed COCP reported a wider $3.44 million quarterly loss alongside Phase 1b progress and a $5 million OPKO investment.
Viking Therapeutics Takeover Chatter Puts VKTX Back in the M&A Spotlight
Renewed takeover interest lifted VKTX shares, sharpening the debate over obesity-drug consolidation and the risks of M&A-driven repricing.
Sellas Life Sciences Surges 17% Ahead of Potentially Transformative AML Data
Sellas Life Sciences shares jumped 17% after hours as investors positioned for the company’s expected Phase 3 AML readout this month.
Candel Therapeutics Target Cut to $19 as BLA Delay Raises Regulatory Risk
Stifel cut Candel Therapeutics’ target to $19 after a BLA delay, while the biotech continues FDA discussions and readiness work.
Rezolute Stock Jumps 7.8% as Tumor Hypoglycemia Data Set Up FDA Catalyst
Rezolute shares rose 7.8% pre-market after tumor hypoglycemia data, with FDA discussions planned for Q1 2027 as topline results remain pendi…
Denali Therapeutics Gets Bullish Wells Fargo Initiation on Hunter Syndrome Drug
Wells Fargo initiated Denali Therapeutics at overweight, putting fresh sell-side attention on its approved Hunter Syndrome therapy, Avlayah.
Altimmune’s Wider Q3 Loss Puts the Spotlight on Its $480 Million Clinical Runway
Altimmune’s wider Q3 loss sharpens the balance-sheet debate as $480 million supports pemvidutide’s ongoing liver-disease trials.
FDA Fast-Track Shutdown Raises Approval-Timeline Risks for Biotech Investors
The reported end of the FDA Fast-Track program could lengthen approval timelines, while SPY valuation reportedly remained steady.
Biotech Traders Face a Year-End Wave of FDA Catalysts for BBIO and VRTX
Priority reviews for BBIO and VRTX create a concentrated late-2026 FDA calendar spanning muscle disease, kidney disease, cancer, pain and ep…
CanaRx Arrests Put Cross-Border Prescription Drug Importation Under the Microscope
The arrests of two CanaRx officials sharpen questions about U.S.-Canada drug trade, discount pricing models and regulatory oversight.
ImmunityBio Stock Faces a Sentiment Test as Anktiva Catalysts Collide With a Sharp Weekly Selloff
IBRX is on pace for its worst week in nearly two years even as Anktiva gains a broader approval and a year-end FDA filing approaches.











